Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open‐label study

A previous dose‐finding study has suggested that romiplostim is effective in patients with refractory aplastic anaemia (AA) and 10 µg/kg once weekly was recommended as a starting dose. In this Phase II/III, multicentre, open‐label study, romiplostim was administered subcutaneously at a fixed dose of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Jun Ho, Tomiyama, Yoshiaki, Miyazaki, Koji, Nagafuji, Koji, Usuki, Kensuke, Uoshima, Nobuhiko, Fujisaki, Tomoaki, Kosugi, Hiroshi, Matsumura, Itaru, Sasaki, Ko, Kizaki, Masahiro, Sawa, Masashi, Hidaka, Michihiro, Kobayashi, Naoki, Ichikawa, Satoshi, Yonemura, Yuji, Enokitani, Kouki, Matsuda, Akira, Ozawa, Keiya, Mitani, Kinuko, Lee, Jong Wook, Nakao, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Red Cells and Iron
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821109/
https://www.ncbi.nlm.nih.gov/pubmed/33152120
http://dx.doi.org/10.1111/bjh.17190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821109/
https://www.ncbi.nlm.nih.gov/pubmed/33152120
http://dx.doi.org/10.1111/bjh.17190

Ejemplares similares